Navigation Links
Researchers find genetic risk factor for pulmonary fibrosis
Date:5/21/2013

AURORA, Colo. (May 21, 2013) A paper recently published in the New England Journal of Medicine and co-written by physicians and scientists at the University of Colorado School of Medicine finds that an important genetic risk factor for pulmonary fibrosis can be used to identify individuals at risk for this deadly lung disease.

Researchers looked at a fairly common variant of the gene for mucin-5B, a protein that is a component of the mucous produced by the bronchial tubes. While this variant of the MUC5B gene is fairly common, pulmonary fibrosis is an uncommonly reported disease.

In a review of CT scans of more than 2,600 adults who did not have a clinical diagnosis of pulmonary fibrosis, researchers found imaging evidence of lung inflammation and scarring in about 9 percent of those over age 50. In this age group, these abnormal findings on CT scans were significantly more common among the 21 percent people with the MUC5B genetic variant.

Importantly, definite lung fibrosis seen on CT scan was strongly associated with the MUC5B genetic variant. While these abnormalities do not necessarily indicate a disease that will progress, the presence of these abnormalities were associated with more shortness of breath and cough as well as smaller lung sizes and ability to transfer oxygen.

The findings suggest that pulmonary fibrosis, which is a condition where lung tissue becomes thickened, stiff and scarred, may be a part of a much more common, but likely less severe, syndrome and could potentially be predicted on the basis of the MUC5B genetic variant.

David A. Schwartz, MD, chairman of the School of Medicine's Department of Medicine, was a corresponding and senior author of the paper. Gary M. Hunninghake, MD, MPH, from the pulmonary and critical care division of the Department of Medicine at Brigham and Women's Hospital in Boston was a corresponding and first author of the paper. The research is supported by grants from the National Institutes of Health, the National Heart, Lung and Blood Institute and the U.S. Veterans Administration.

Twenty-one authors shared credit for the paper, including researchers from Brigham and Women's Hospital and Boston University. Joining Schwartz from Colorado were Elissa Murphy, MS, and Marvin I. Schwarz, MD, from the School of Medicine and Tasha E. Fingerlin, PhD, from the Colorado School of Public Health.

David Schwartz this month gave the American Thoracic Society's Amberson Lecture, an honor bestowed annually on an individual with a career of major lifetime contributions to clinical or basic pulmonary research and/or clinical practice.


'/>"/>

Contact: Mark Couch
mark.couch@ucdenver.edu
303-724-5377
University of Colorado Denver
Source:Eurekalert

Related medicine news :

1. Researchers find genetic tie to improved survival time for pulmonary fibrosis
2. Leading researchers report on the elusive search for biomarkers in Huntingtons disease
3. Dissertation Clinic Prescribes Customized Remedy for Researchers
4. AGA honors distinguished clinicians, researchers and educators with prestigious recognition awards
5. Moffitt Cancer Center researchers analyze how Spanish smoking relapse booklets are distributed
6. Researchers say they are shocked by new statistics on head injuries among people who are homeless
7. A Premium Service for Researchers Launched in Switzerland
8. Two Leading Alzheimer's Disease Researchers Recognized with MetLife Foundation Awards
9. PolyU Researchers Develop Novel Brain Training Device to Reconnect the Brain and Paralyzed Limb After Stroke
10. University of Colorado Researchers Find Dual Chamber Defibrillators Pose Higher Risk of Complications
11. Leap in leukemia treatment reported by Dartmouth researchers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/25/2017)... ... April 25, 2017 , ... As pharmaceutical companies are held ... with process innovation in drug formulation and manufacturing. CoreRx offers its clients ... equipment in support of their development and manufacturing goals. , The company ...
(Date:4/25/2017)... ... April 25, 2017 , ... Back Pain Centers ... back pain with a reputable physician in their area, announces the launch of a ... information for patients who are looking for reputable physicians to help them with back ...
(Date:4/25/2017)... ... April 25, 2017 , ... Saad B. Chaudhary, MD is committed to providing the highest ... chronic problems, I focus on preventative care with all my patients to alleviate possible future ... always feel free to contact my office and my trained staff will assist you in ...
(Date:4/25/2017)... ... April 25, 2017 , ... Emergency Physician and Distinguished Professor of Emergency ... Series, Outliers in Writing, set to publish in summer 2017. , Dr. Bobrow, ... University of Arizona College of Medicine. He also serves as Medical Director for the ...
(Date:4/25/2017)... ... ... Vetoquinol USA® , a world-class developer of veterinarian-approved ... EQUISTRO line, at this week’s Rolex Kentucky Three-Day Event in Lexington. Flexadin UCII ... The scientifically-developed Flexadin UCII supports the body’s normal repair of cartilage and joints. ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... April 20, 2017  RXi Pharmaceuticals Corporation (NASDAQ: ... that address significant unmet medical needs, today announced ... Company,s consumer product development program, based on its ... for Investigative Dermatology (SID) 76 th Annual ... promote the sciences relevant to skin health and ...
(Date:4/20/2017)... 2017  AbbVie (NYSE: ABBV), a global biopharmaceutical ... chronic hepatitis C virus (HCV) infected patients with ... compensated cirrhosis (Child-Pugh A) achieved sustained virologic response ... its investigational, pan-genotypic regimen of glecaprevir/pibrentasvir (G/P). These ... 12 weeks of G/P treatment without ribavirin. Patients ...
(Date:4/20/2017)... Research and Markets has announced the addition of ... By Service (Manufacturing, Research), By Country, (Brazil, Mexico, Colombia, Argentina, ... to their offering. ... The Latin American pharmaceutical contract manufacturing services market is anticipated ... drug registration cost in Latin American countries and continuous economic ...
Breaking Medicine Technology: